DSIP — The Peptide That Targets
Your Sleep Architecture

Peptide type

Nonapeptide (9 amino acids)

Primary site of action

Thalamic and hypothalamic sleep-regulatory circuits

Sleep stage targeted

N3 slow-wave sleep (delta waves, 0.5–4 Hz)

Secondary effects

Cortisol modulation, HPA axis normalization

Dependency profile

None identified — no tolerance development

Morning sedation carry-over

None — no impairment to daytime alertness

Direct Thalamic Delta Wave Promotion

DSIP acts on thalamocortical circuits, the same circuits responsible for generating the synchronized delta wave oscillations (0.5–4 Hz) that define N3 slow-wave sleep. Rather than suppressing wakefulness broadly, DSIP signals within the architecture of sleep itself, promoting the conditions under which delta activity naturally occurs.

Cortisol and HPA Axis Modulation

Elevated evening cortisol is one of the most common physiological barriers to deep sleep. DSIP has been shown to reduce excess cortisol secretion and normalize HPA axis tone, lowering the hormonal interference that prevents patients from reaching and sustaining N3.

No Dependency: Works Within Endogenous Circuits

Because DSIP acts within the brain's natural sleep-generating machinery rather than overriding it, it does not produce the tolerance or rebound insomnia associated with sedative compounds. Patients don't need to increase the dose over time to maintain efficacy.

Stress-Induced Sleep Disruption

DSIP shows particular benefit in patients whose sleep disruption is driven by psychological or physiological stress, including elevated allostatic load, night-time cortisol spikes, and stress-sensitized arousal thresholds. DSIP addresses both the downstream effect (poor delta wave activity) and the upstream driver (dysregulated HPA output) simultaneously.

N3 is where the most physiologically meaningful work of sleep happens: tissue repair, immune consolidation, GH secretion, and synaptic pruning. DSIP promotes the architecture that makes sleep regenerative.

Because DSIP promotes natural delta wave activity rather than suppressing the CNS broadly, there is no morning sedation hangover. Patients report feeling genuinely rested rather than chemically blunted.

Patients whose sleep disruption stems from elevated cortisol, anxiety, or chronic stress often see the most dramatic response. DSIP's HPA modulation addresses the physiological root of the problem.

DSIP can be used in structured protocols without the progressive dose escalation, rebound insomnia, or physical dependency that complicate long-term use of most sleep medications.

The pulsatile growth hormone release stimulated by secretagogues like CJC-1295/Ipamorelin or Sermorelin occurs primarily during N3 slow-wave sleep. DSIP deepens the sleep stage those compounds depend on.

The Patient Who Sleeps Enough But Wakes Unrefreshed

Seven or eight hours in bed, but never feeling like they actually recovered. Tracking data shows minimal time in deep sleep. The hours are there, but the architecture is not. DSIP is the most direct available intervention for this pattern.

High-Stress, High-Cortisol Patients

Chronic stress, demanding careers, athletes in heavy training blocks, anyone whose HPA axis is running hot at night. Elevated cortisol is structurally incompatible with deep sleep.

Patients Currently Using GH Secretagogues

CJC-1295/Ipamorelin, Sermorelin, or Tesamorelin patients not seeing expected body composition and recovery benefits may simply be failing to reach adequate N3 depth for GH pulsatility to occur.

The Patient Who Wants to Avoid Sedating Compounds

Patients who have experienced or want to avoid the dependence, morning impairment, or rebound insomnia of pharmaceutical sleep aids, but whose sleep is genuinely disrupted enough to warrant clinical intervention.

Age-Related Sleep Architecture Degradation

Deep sleep time declines significantly with age. N3 can decrease by more than 50% between early adulthood and middle age. DSIP directly targets the delta wave output that natural aging suppresses.

Typical Starting Dose

100–200mcg subcutaneously, administered 30–60 minutes before intended sleep time. The 2mg/mL (5mL) vial allows flexible dosing within this range throughout the course of a protocol.

Administration Timing

Pre-sleep subcutaneous injection, 30 to 60 minutes before bed is standard. Unlike sedatives, DSIP does not produce an onset effect you need to be in bed for.

Cycle Structure

DSIP is typically used in defined cycles; common protocols run 5 nights on / 2 nights off, or nightly for 4–8 weeks followed by a structured break. Because DSIP does not produce tolerance, cycling is for protocol management rather than dependency prevention.

Stacking Considerations

DSIP pairs particularly well with CJC-1295/Ipamorelin or Sermorelin. DSIP deepens the N3 architecture, while GH secretagogues amplify the pulsatile GH release that occurs within it. Epithalon is another common stack partner.